These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37348410)

  • 21. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
    Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
    J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of responsive neurostimulation (RNS) on neuropsychiatric and psychosocial outcomes in drug-resistant epilepsy.
    Tager D; Panjeti-Moore D; Yang JC; Rivera-Cruz A; Loring DW; Staikova E; Block C; Bullinger KL; Rodriguez-Ruiz AA; Cabaniss BT; Winkel D; Bonilha L; Willie JT; Gross RE; Drane DL; Karakis I
    Epilepsy Behav; 2023 May; 142():109207. PubMed ID: 37075511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expected Budget Impact and Health Outcomes of Expanded Use of Vagus Nerve Stimulation Therapy for Drug-Resistant Epilepsy.
    Purser MF; Mladsi DM; Beckman A; Barion F; Forsey J
    Adv Ther; 2018 Oct; 35(10):1686-1696. PubMed ID: 30143957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
    Parasuraman S; Thiel E; Park J; Teschemaker A
    J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
    Lu M; Oladapo A; Wu Y; Farahbakhshian S; Ewenstein B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
    [No Abstract]   [Full Text] [Related]  

  • 29. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic burden associated with tuberous sclerosis complex in patients with epilepsy.
    Betts KA; Stockl KM; Yin L; Hollenack K; Wang MJ; Yang X
    Epilepsy Behav; 2020 Nov; 112():107494. PubMed ID: 33181900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Cost Sarcoidosis Patients in the United States: Patient Characteristics and Patterns of Health Care Resource Utilization.
    Rice JB; White A; Lopez A; Nelson WW
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1261-1269. PubMed ID: 29172980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
    Baser O; Chalk M; Rawson R; Gastfriend DR
    Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
    Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
    J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of pharmacotherapy regimen and costs in patients with drug-resistant epilepsy following vagus nerve stimulation therapy: a single-center study (Poland).
    Kopciuch D; Barciszewska AM; Fliciński J; Zaprutko T; Kus K; Steinborn B; Nowakowska E
    Acta Neurol Belg; 2020 Feb; 120(1):115-122. PubMed ID: 31721076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
    Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
    J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany.
    Strzelczyk A; Schubert-Bast S; Bast T; Bettendorf U; Fiedler B; Hamer HM; Herting A; Kalski M; Kay L; Kieslich M; Klein KM; Kluger G; Kurlemann G; Mayer T; Neubauer BA; Polster T; von Spiczak S; Stephani U; Trollmann R; Wiemer-Kruel A; Wolff M; Irwin J; Carroll J; Pritchard C; Rosenow F
    Epilepsia; 2019 Aug; 60(8):1697-1710. PubMed ID: 31247127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Claims data analyses unable to properly characterize the value of neurologists in epilepsy care.
    Hill CE; Lin CC; Burke JF; Kerber KA; Skolarus LE; Esper GJ; Magliocco B; Callaghan BC
    Neurology; 2019 Feb; 92(9):e973-e987. PubMed ID: 30674587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.